Sub-Saharan Africa
Sputnik brings you all the most recent information, major events, heroes and views, including breaking news, images, videos, analyses, and features.

South Africa to Produce HIV-Prevention Medication

© AP Photo / Denis FarrellLaboratory technicians test a blood sample for HIV infection at the Reproductive Health and HIV Institute (RHI) in Johannesburg,Thursday, Nov. 26 2020
Laboratory technicians test a blood sample for HIV infection at the Reproductive Health and HIV Institute (RHI) in Johannesburg,Thursday, Nov. 26 2020 - Sputnik Africa, 1920, 19.05.2023
Subscribe
The World Health Organization (WHO) characterized HIV-prevention drug CAB-LA as a "safe and highly effective prevention option for people at substantial risk of HIV infection" in 2022. One of the medicine's creators, ViiV Healthcare has the patent on CAB-LA in South Africa until 2031, which limits competition.
South Africa is poised to become a manufacturing hub for an affordable version of the groundbreaking HIV-prevention drug CAB-LA (cabotegravir long-acting), reports have indicated.
The country will prospectively provide access to the drug to millions of people in a region that accounts for nearly two-thirds of new HIV infections globally, according to the World Health Organization.
The medication will be produced by Cipla Limited, a leading Indian multinational pharmaceutical company, at its plants in either Benoni or Durban.
The move reflects a growing recognition of the urgent need to address the staggering rates of HIV infection in sub-Saharan Africa, where access to critical medications can be limited by high costs and logistical challenges.
 A nurse prepares to administer an AstraZeneca vaccination against COVID-19, at a district health center giving first, second, and booster doses to eligible people, in the low-income Kibera neighborhood of Nairobi, Kenya, Jan. 20, 2022.  - Sputnik Africa, 1920, 24.04.2023
Features
World Immunization Week: What Challenges Does Africa Face?
Researchers have demonstrated that the medication lowers the likelihood of catching the virus through intercourse and is supposed to stop HIV from entering cells, significantly decreasing the risk of infection.
Three companies, Aurobindo, Cipla, and Viatris, inked sublicense agreements in March, according to the drug's creators, Viiv Healthcare and the United Nations-backed public health nonprofit Medicines Patent Pool (MPP), to make the generic version.
According to the MPP, the chosen firms will be able to create and provide generic versions in 90 countries "subject to required regulatory approvals being obtained."
The MPP also stated that the medication is given as an injection six times a year and is started with a single 600mg (3ml) shot given to an individual two months in a row apart. However, in order to receive it, a person must first have a negative HIV-1 test.
Newsfeed
0